Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030

Pages: 108 Published: December 09, 2021 Report Code: GDHC232PIDR

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    TTS

The global plaque psoriasis (PsO) market was valued at $14.2 billion in 2020 and is projected to record a growth of more than 6% during the forecast period 2021-2030. The major growth drivers of the global PsO market are new product launches, a steady increase in total diagnosed prevalence across the 7MM, and increased treatment options for mild and moderate patients. The major barriers to growth in the PsO market during the forecast period include loss of patent expiry and key biosimilar launches of gold-standard biologics and the launch of apremilast generics.

Global plaque psoriasis market overview

Global plaque psoriasis market overview

For more insights on this report, download a free report sample

What are the market dynamics in the global plaque psoriasis market?

The PsO affects both sexes and all races, ethnicities, and ages. However, the disease is more prevalent in adults than children. The prevalence of PsO also varies geographically and is more prevalent in countries with higher incomes and regions with older populations. Differences in the reported prevalence between countries may be due to variations in environmental factors and genetic factors. Compared to adults, the pediatric prevalence of PsO in the 7MM was much lower, with 0.17% of boys and 0.24% of girls receiving a diagnosis. The disparity in prevalence between children and adults was observed across all markets. Among children, Japan had the lowest prevalence of PsO in boys. In comparison, France had the highest estimated prevalence with 0.44%, while in girls, the prevalence ranged from 0.06% in Japan to 0.83% in France.

In addition, In the 7MM, the lifetime diagnosed prevalent cases of PsO will increase. In 2020, the US accounted for 47% of lifetime diagnosed prevalent cases of PsO in the 7MM, with 7,477,120 cases, in men and women. Among the 5EU markets, Germany had the greatest number of prevalent cases with 1,747,675 cases, contributing over 10% of lifetime diagnosed prevalent cases of PsO in the 7MM. Conversely, Spain had the lowest number of prevalent cases with 926,456 cases, contributing to over 4% of lifetime diagnosed prevalent cases in 7MM. In 2020, Japan accounted for the lowest percentage of diagnosed prevalent cases of PsO in the 7MM, resulting in 470,089 cases. However, cases in Japan are expected to grow at an Annual Growth Rate (AGR) of over 0.05% to 473,815 cases in 2030. Of the 7MM, the US is expected to see the most significant growth from 7,477,120 lifetimes diagnosed prevalent cases in 2020 to 8,171,859 cases in 2030, occurring at an AGR of over 0.5%. Germany is the only country in the 7MM where cases will decrease between 2020 and 2030, with an ARG of negative 0.04%. This decrease will result in 1,739,834 cases in 2030, down from 1,747,675 cases in 2020. Within the 5EU, France had the highest number of lifetimes diagnosed with prevalent cases of PsO with 2,107,634 cases, while Spain had the fewest with 926,456 cases. In 2030, France will continue to have the most lifetime diagnosed prevalent cases of PsO in the 5EU with 2,185,493 cases, after growing at an AGR of over 0.30%. Likewise, Spain will continue to have the fewest lifetime diagnosed prevalent cases of PsO with 943,870 cases after growing at an AGR of 0.19%.

Which are the key countries in the global plaque psoriasis market?

The US is the largest PsO market, representing over 79% of 2020 global sales. The most notable factor limiting the growth of the market is the loss of several key biologic patents (and anticipated biosimilar launches) across several different classes. Although similar dynamics are expected to be at play for IL-17 inhibitors Cosentyx (secukinumab) and Taltz (ixekizumab), both drugs are expected to remain on patent until the second half of the forecast period, which protects their growth potential for much of the forecast. Additionally, three new IL-17 inhibitors are expected to launch in this market: UCB Pharma’s Bimzelx (bimekizumab), Merck’s sonelokimab, and Affibody’s ABY-035/izokibep. With these factors in mind, the IL-17 inhibitor class sales are expected to grow at a CAGR of over 11%, with combined 2030 sales of over $7 billion. In addition, Combined, the 5EU (France, Germany, Italy, Spain, and the UK) comprised of over 12% of 2020 global sales, with a combined valuation. Across the 5EU, Germany emerged as the highest-grossing country by value in 2020, with estimated PsO sales of over $600 million, followed by the UK, Italy, Spain, and lastly France. Germany is anticipated to remain the highest-grossing market in the 5EU in 2030, generating sales of over $1 billion followed by the UK, Italy, Spain, and lastly France.

Global plaque psoriasis market, by key country

Global plaque psoriasis market, by key country

For more regional insights, download a free report sample

Which are the major players in the global plaque psoriasis market?

The major players in the global plaque psoriasis market are AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy’s Laboratories, Arcutis Biotherapeutics, Affibody, Merck, and Can-Fite BioPharma.

Global plaque psoriasis market, by key players

Global plaque psoriasis market, by key players

To know more about key players, download a free report sample

Market report scope

Market value (Year-2020) $14.2 billion
Growth rate (CAGR) >6%
Base year for estimation 2020
Forecast period 2021-2030
Key Players AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy’s Laboratories, Arcutis Biotherapeutics, Affibody, Merck, and Can-Fite BioPharma

Scope

  • Overview of PsO including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline PsO market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsO therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global PsO therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

  • The greatest drivers of growth in the global PsO market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the PsO market include the patent expiration of several key biologics and small molecules.
  • Among the late-stage innovator pipeline products, three are injectable biologics, three are oral small molecules, and two are topical small molecules.
  • The most important unmet needs in the PsO market are increased access to therapies as well as therapies that can target multiple disease domains.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global PsO therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsO market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global PsO therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

AbbVie

Pfizer

Johnson & Johnson (J&J)

Bristol-Myers Squibb

UCB Pharma

Amgen

Novartis

Eli Lilly

Sun Pharma

Dermavant

Arcutis Biotherapeutics

Merck

Dr. Reddy’s Laboratories

Affibody

Can-Fite BioPharma

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Plaque Psoriasis: Executive Summary

1.1 PsO Market to Experience Conservative Growth from 2020–2030

1.2 New Players to Enter a Saturated Field

1.3 Opportunities Remain for Undertreated Patient Populations

1.4 Innovator Small Molecules Dominate the Late-Stage Pipeline

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources Used

4.4.2 Forecast Assumptions and Methods

4.5 Epidemiological Forecast for PsO (2020–2030)

4.5.1 Lifetime Diagnosed Prevalent Cases of PsO

4.5.2 Age–Specific Lifetime Diagnosed Prevalent Cases of PsO

4.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of PsO

4.5.4 Lifetime Diagnosed Prevalent Cases of PsO by Severity in the Adult Population

4.5.5 Lifetime Diagnosed Prevalent Cases of PsO with PsA in the Adult Population

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis

5.2 Treatment

5.2.1 Impact of COVID-19

6 Competitive Assessment

6.1 Overview

6.1.1 TNF Inhibitors

6.1.2 IL-17 Inhibitors

6.1.3 IL-23 Inhibitors

6.1.4 Other Disease Modifying Therapies

6.2 Biosimilars

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Cost-Effective Therapies

7.3 Efficacious Therapies for Treatment Refractory Patients

7.4 Lack of Innovative Topical Therapies

7.5 Treatment Options for Mild PsO Patients

8 R&D Strategies

8.1 Overview

8.1.1 Development Shift Away from Injectable Biologics

8.1.2 New Players Enter the Late-Stage Pipeline

8.2 Clinical Trials Design

8.2.1 Robust Clinical Endpoints

8.2.2 Long-Term Patient Follow-Up

8.2.3 Active Comparator Trials

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Bimzelx (bimekizumab)

9.2.2 Sonelokimab/M1095

9.2.3 ABY-035/izokibep

9.2.4 Tapinarof/DMVT-505

9.2.5 Roflumilast

9.2.6 Deucravacitinib

9.2.7 Piclidenoson

9.2.8 Tepilamide fumarate

9.3 Other Drugs of Note

9.3.1 Mirikizumab

9.3.2 Brepocitinib tosylate

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Biologic Medications

10.2.2 Small Molecule Therapeutics

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs and Payors Interviewed for This Report

13.4.1 KOLs

13.4.2 Payors

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Therapy Area Director

13.6.4 Epidemiologist

13.6.5 Reviewers

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Plaque Psoriasis: Key Metrics in the 7MM

Table 2: Risk Factors and Comorbidities for PsO

Table 3: Classification of PsO by BSA

Table 4: Treatment Guidelines for Plaque Psoriasis

Table 5: Top Completed Deals in PsO Market by Value, 2016–2021

Table 6: PsO Market – Global Drivers and Barriers, 2020–2030

Table 7: Key Events Impacting Sales for PsO in the US, 2020–2030

Table 8: PsO Market – Drivers and Barriers in the US, 2020–2030

Table 9: Key Events Impacting Sales for PsO in the 5EU, 2020–2030

Table 10: PsO Market – Drivers and Barriers in the 5EU, 2020–2030

Table 11: Key Events Impacting Sales for PsO in Japan, 2020–2030

Table 12: PsO Market – Drivers and Barriers in Japan, 2020–2030

Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for PsO in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in PsO During the Forecast Period

Figure 3: Competitive Assessment of the Pipeline/Recently Approved Biologic Drugs Benchmarked Against the SOC, Humira

Figure 4: Competitive Assessment of the Pipeline Small Molecules Drugs Benchmarked Against the SOC, Otezla (apremilast)

Figure 5: Biologic Targets in the Treatment of PsO

Figure 6: 7MM, Lifetime Diagnosed Prevalence of Pediatric PsO (%), Boys and Girls, Ages ≤17 Years, 2020

Figure 7: 7MM, Lifetime Diagnosed Prevalence of Adult PsO (%), Men and Women, Ages ≥18 Years, 2020

Figure 8: Sources Used for Lifetime Diagnosed Prevalent Cases of Pediatric PsO

Figure 9: Sources Used and Not Used for Lifetime Diagnosed Prevalent Cases of PsO in Adults

Figure 10: Sources Used for Lifetime Diagnosed Prevalent Cases of PsO by Severity Among Adults

Figure 11: Sources Used for Lifetime Diagnosed Prevalent Cases of PsO with PsA Among Adults

Figure 12: 7MM, Lifetime Diagnosed Prevalent Cases of PsO, Men and Women, All Ages, 2020 (N)

Figure 13: Age-Specific Lifetime Diagnosed Prevalent Cases of PsO, 7MM, Men and Women, 2020 (N)

Figure 14: 7MM, Sex-Specific Lifetime Diagnosed Prevalent Cases of PsO, All Ages, 2020 (N)

Figure 15: 7MM, Lifetime Diagnosed Prevalent Cases of PsO by Severity, Men and Women, ≥18 Years, 2020

Figure 16: 7MM, Lifetime Diagnosed Prevalent Cases of PsO with Psoriatic Arthritis, Men and Women, ≥18 Years, 2020 (N)

Figure 17: Overall Treatment Algorithm for PsO and PsO/PsA

Figure 18: Unmet Needs and Opportunities in PsO

Figure 19: Overview of the Development Pipeline in PsO

Figure 20: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PsO in the 7MM During the Forecast Period

Figure 21: Competitive Assessment of the Pipeline/Recently Approved Biologic Drugs Benchmarked Against the SOC, Humira (adalimumab)

Figure 22: Competitive Assessment of the Pipeline Small Molecules Drugs Benchmarked Against the SOC, Otezla (apremilast)

Figure 23: Analysis of the Company Portfolio Gap in PsO During the Forecast Period

Figure 24: Global (7MM) Sales Forecast by Country for PsO in 2020 and 2030

Figure 25: Sales Forecast by Class for PsO in the US in 2020 and 2030

Figure 26: Sales Forecast by Class for PsO in the 5EU in 2020 and 2030

Figure 27: Sales Forecast by Class for PsO in Japan in 2020 and 2030

Frequently Asked Questions

The global plaque psoriasis market was valued at $14.2billion in 2020.

 

 

 

 

The global plaque psoriasis market is projected to record a growth of more than 6% during the forecast period 2021-2030.

The major players in the global plaque psoriasis market are AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy’s Laboratories, Arcutis Biotherapeutics, Affibody, Merck, and Can-Fite BioPharma.

$10995

Can be used by individual purchaser only

$32985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.